Director/PDMR Shareholding - Replacement

The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 8 May 2015.

The grant date of the award of shares has been corrected to September 2014 from September 2015.

All other details remain unchanged.

The full amended text is shown below.

Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

On 7 May 2015, the interest of Luke Miels, a person discharging managerial responsibilities, in AstraZeneca PLC Ordinary Shares of $0.25 each changed as detailed below.

The change in interest relates to the vesting on 7 May 2015 of an award of shares granted in September 2014 under the AstraZeneca Restricted Share Plan. In accordance with the terms of the award, Mr Miels has become beneficially entitled to all of the shares originally awarded.

Sufficient vested shares have been withheld to cover certain tax obligations arising on the vesting and the net number of shares has been delivered into a personal brokerage account.

Plan Shares   awarded Shares   vested Shares   withheld Net   shares received
AstraZeneca Restricted Share Plan 7,776 7,776 2,791 4,985

For tax purposes, the fair market value of the shares at vest was 4413.5 pence per share being the closing price of AstraZeneca shares on the last trading day preceding the vesting day.

A C N Kemp

Company Secretary

8 May 2015

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links